Mirum Pharmaceuticals Files Q1 2025 10-Q

Ticker: MIRM · Form: 10-Q · Filed: May 7, 2025 · CIK: 1759425

Sentiment: neutral

Topics: 10-Q, pharmaceuticals, financials

TL;DR

Mirum Pharma's Q1 2025 10-Q is in. Check financials.

AI Summary

Mirum Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business segment information are presented, reflecting the company's ongoing activities in the pharmaceutical sector.

Why It Matters

This filing provides investors and analysts with the latest financial health and operational status of Mirum Pharmaceuticals, crucial for understanding its market position and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Mirum faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What were Mirum Pharmaceuticals' total revenues for the first quarter of 2025?

The filing indicates revenue data for the period January 1, 2025 to March 31, 2025, but specific total revenue figures are not explicitly stated in the provided text snippet.

What is the company's primary business segment?

The company's business involves 'Pharmaceutical Preparations' (SIC code 2834) and mentions 'productCandidate' and 'medicine'.

When is Mirum Pharmaceuticals' fiscal year end?

Mirum Pharmaceuticals' fiscal year ends on December 31.

Where is Mirum Pharmaceuticals headquartered?

Mirum Pharmaceuticals is headquartered at 989 East Hillsdale Boulevard, Suite 300, Foster City, CA 94404.

What is the SEC file number for Mirum Pharmaceuticals?

The SEC file number for Mirum Pharmaceuticals is 001-38981.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Mirum Pharmaceuticals, Inc. (MIRM).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing